Reviewing Clarus Therapeutics (NASDAQ:CRXT) & Ayala Pharmaceuticals (NASDAQ:AYLA)
Reviewing Clarus Therapeutics (NASDAQ:CRXT) & Ayala Pharmaceuticals (NASDAQ:AYLA)
Ayala Pharmaceuticals (NASDAQ:AYLA – Get Rating) and Clarus Therapeutics (NASDAQ:CRXT – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.
阿亞拉制藥(納斯達克：Ayla-GET評級)和克拉魯斯治療(納斯達克：CRXT-GET評級)都是小盤醫療公司，但哪項業務更優越？我們將根據兩家公司的收益、股息、風險、機構所有權、估值、盈利能力和分析師的建議來比較它們的實力。
Analyst Recommendations
分析師建議
This is a summary of current ratings for Ayala Pharmaceuticals and Clarus Therapeutics, as provided by MarketBeat.com.
這是MarketBeat.com提供的Ayala製藥公司和Clarus治療公司的當前評級摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ayala Pharmaceuticals | 0 | 0 | 6 | 0 | 3.00 |
| Clarus Therapeutics | 0 | 2 | 2 | 0 | 2.50 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 阿亞拉制藥公司 | 0 | 0 | 6 | 0 | 3.00 |
| 克拉魯斯治療公司 | 0 | 2 | 2 | 0 | 2.50 |
Ayala Pharmaceuticals presently has a consensus target price of $15.33, suggesting a potential upside of 823.69%. Clarus Therapeutics has a consensus target price of $7.90, suggesting a potential upside of 3,776.35%. Given Clarus Therapeutics' higher probable upside, analysts plainly believe Clarus Therapeutics is more favorable than Ayala Pharmaceuticals.
Ayala PharmPharmticals目前的共識目標價為15.33美元，暗示潛在上漲823.69%。Clarus治療公司的共識目標價為7.90美元，這意味着潛在的上漲幅度為3776.35%。鑑於Clarus治療公司更有可能上行，分析師們顯然認為Clarus治療公司比Ayala製藥公司更有利。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Ayala Pharmaceuticals | -1,749.29% | -131.63% | -107.62% |
| Clarus Therapeutics | -193.00% | N/A | -87.75% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 阿亞拉制藥公司 | -1,749.29% | -131.63% | -107.62% |
| 克拉魯斯治療公司 | -193.00% | 不適用 | -87.75% |
Insider and Institutional Ownership
內部人與機構持股
56.1% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 19.5% of Clarus Therapeutics shares are held by institutional investors. 3.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Clarus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Ayala PharmPharmticals 56.1%的股份由機構投資者持有。相比之下，Clarus Treateutics 19.5%的股份由機構投資者持有。Ayala PharmPharmticals 3.6%的股份由公司內部人士持有。相比之下，Clarus Treateutics 5.3%的股份由公司內部人士持有。強大的機構持股表明，大型基金管理公司、對衝基金和捐贈基金相信，一家公司的長期表現將好於大盤。
Earnings and Valuation
收益和估值
This table compares Ayala Pharmaceuticals and Clarus Therapeutics' gross revenue, earnings per share and valuation.
此表比較了Ayala製藥公司和Clarus治療公司的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ayala Pharmaceuticals | $3.51 million | 6.98 | -$40.25 million | ($2.54) | -0.65 |
| Clarus Therapeutics | $13.96 million | 0.76 | -$40.62 million | ($1.30) | -0.16 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 阿亞拉制藥公司 | 351萬美元 | 6.98 | -4,025萬美元 | ($2.54) | -0.65 |
| 克拉魯斯治療公司 | 1,396萬美元 | 0.76 | -4,062萬美元 | ($1.30) | -0.16 |
Ayala Pharmaceuticals has higher earnings, but lower revenue than Clarus Therapeutics. Ayala Pharmaceuticals is trading at a lower price-to-earnings ratio than Clarus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ayala製藥公司的收益比Clarus治療公司高，但收入比Clarus治療公司低。Ayala PharmPharmticals的市盈率低於Clarus Treeutics，這表明它目前是兩隻股票中更負擔得起的一隻。
Risk & Volatility
風險與波動性
Ayala Pharmaceuticals has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500. Comparatively, Clarus Therapeutics has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.
Ayala PharmPharmticals的貝塔係數為2.36，這表明其股價的波動性比標準普爾500指數高136%。相比之下，Clarus Treateutics的貝塔係數為1.44，這表明其股價的波動性比標準普爾500指數高44%。
Summary
摘要
Clarus Therapeutics beats Ayala Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Clarus治療公司在兩隻股票比較的14個因素中有8個擊敗了Ayala製藥公司。
About Ayala Pharmaceuticals
關於阿亞拉制藥公司
(Get Rating)
(獲取評級)
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Ayala製藥公司是一家臨牀階段的腫瘤學公司，專注於為患有罕見和侵襲性癌症的患者開發和商業化小分子療法。該公司的主要候選產品是AL101，這是一種有效、選擇性和可注射的小分子伽馬分泌酶抑制劑(GSI)，目前處於第二階段臨牀試驗，用於治療攜帶Notch激活突變的患者的復發/轉移性腺樣囊性癌。它還參與了AL102的開發，這是一種有效的、選擇性的口服小分子GSI，正在進行第二階段/第三階段的關鍵研究，用於治療韌帶樣瘤。Ayala製藥公司與諾華國際製藥有限公司達成了一項合作協議，開發用於治療多發性骨髓瘤的AL102。該公司成立於2017年，總部設在以色列雷霍沃特。
About Clarus Therapeutics
關於Clarus Treateutics
(Get Rating)
(獲取評級)
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
克拉魯斯治療控股公司是一家制藥公司，專注於在美國開發口服睾酮替代療法並將其商業化。它提供JATENZO，一種治療性腺功能減退男性的十一酸睾酮軟凝膠口服制劑。該公司與HavaH Treateutics簽署了一項許可協議，用於治療炎症性乳腺疾病和某些形式的乳腺癌的雄激素療法；並與皇家學習促進學會/麥吉爾大學簽署了一項許可協議，以開發麥吉爾的專利技術並將其商業化，該技術旨在治療與人類輔酶Q10缺陷相關的疾病。克拉魯斯治療控股公司成立於2003年，總部設在伊利諾伊州諾斯布魯克。
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《阿亞拉藥業日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ayala製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。